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Discordance between Train-of-Four Response and Clinical 
Symptoms in a Patient with Amyotrophic Lateral Sclerosis
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A 47-year-old woman with amyotrophic lateral sclerosis was scheduled for total thyroidectomy with 
cervical node dissection.  During anesthetic management by total intravenous anesthesia using remifen-
tanil,  propofol,  and rocuronium,  train-of-four (TOF) monitoring ﬁndings were not consistent with 
clinical signs.  Sugammadex successfully reversed shallow respiration.
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myotrophic lateral sclerosis (ALS) is motor 
neuron disorder,  commonly called Lou Gehrigʼs 
disease.  ALS is known to involve upper and lower 
motor neurons and to lead to death or severe disability 
within a few years [1].  Patient age at disease onset 
and the aﬀected site are the important prognostic fac-
tors of mortality and perioperative course [2].  
Re sponse to neuromuscular blocking agents is more 
sensitive in patients with motor neuron disease,  and 
monitoring of neuromuscular function is an essential 
part of general anesthesia in these patients [3].  How-
ever,  sometimes,  the results of neuromuscular moni-
toring are incompatible with clinical ﬁndings in ALS 
[3].
　 We report an ALS patient with train-of-four 
(TOF) monitoring results in distal limbs that were not 
consistent with respiratory status and reversed 
rocuronium using sugammadex after total intravenous 
anesthesia.
Case Report
　 A 47-year-old,  165-cm tall,  38-kg female was 
scheduled for total thyroidectomy with cervical node 
dissection.  The patient had been diagnosed with ALS 
4 years prior to this presentation,  and had been taking 
phenytoin 2×150mg daily on a regular basis.  Her 
preoperative physical examination showed generalized 
muscle wasting without tongue atrophy,  and her neu-
rological examination revealed grade 4/5 muscle 
strength in upper limbs,  grade 3/5 in lower limbs,  
grade 4/5 for neck ﬂexion/extension,  and hypoactive 
deep tendon reﬂexes without pathologic reﬂexes.  The 
patient reported no slurred speech or dysphagia and 
was of New York Heart Association (NYHA) func-
tional class III.  Spirometry showed a forced vital 
capacity (FVC) of 1.83l (60ｵ of reference),  forced 
expiratory volume in 1 sec (FEV1) of 1.65l (75ｵ),  
and a FEV1/FVC of 90ｵ.  Resting arterial blood gas 
analysis showed a pH of 7.383,  PaCO2 of 38.84mmHg,  
PaO2 of 64.1mmHg,  HCO3－ of 23.3mEq/l,  and 
-SaO2 of 91.8ｵ.  All other biochemistry values were 
within normal limits.  Chest X-ray showed several 
calciﬁed nodules in both upper lung ﬁelds.  She was not 
premedicated and upon arrival at the operating the-
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atre,  standard monitoring devices were applied.  Vital 
signs were 94/64mmHg,  59beats/min,  and SaO2 was 
92ｵ before anesthetic induction.  We ap plied neuro-
muscular monitoring devices (Inner vator; Fisher & 
Paykel Health Care,  Auckland,  New Zealand) on 
orbicularis oculi.  Anesthesia was induced and main-
tained with propofol (target blood concentration 1.5-
3.0µg/ml) and remifentanil (target blood concentra-
tion 0.7-2.5ng/ml),  using a target controlled infusion 
device (Orchestra; Fresenius Kabi,  Bad Homburg,  
Germany).  Schniderʼs and Mintoʼs pharmacokinetic 
models were used to calculate target eﬀect-site con-
centrations for propofol and remifentanil,  respec-
tively.  Three min after administration of rocuronium 
0.3mg/kg,  there was no twitching in response to TOF 
stimulation at 50mA and the patient was intubated.  At 
that time,  the patientʼs lower limbs showed fascicula-
tion with a bucking motion.  Additional rocuronium 
10mg was administered and within 1min,  the fascicu-
lation and bucking disappeared.  Propofol and remifen-
tanil concentrations were adjusted to maintain a 
bispectral index (BIS) score between 40 and 60.  
Because of persistent low blood pressure,  ephedrine 
0.2-0.5mg/kg/h was infused to achieve a target mean 
arterial pressure of over 65mmHg,  throughout the 
operation.  At 90min after anesthetic induction,  an 
additional 5mg of rocuronium was administered due to 
bucking during operative tracheal manipulation without 
TOF response.  Surgery was completed without any 
signiﬁcant sequelae and the total anesthesia time was 
405 min.  At the end of the operation,  all 4 twitches 
of the TOF returned in the orbicularis oculi and the 
ulnar nerve TOF ratio was 0.98 (TOF -Watch SX,  
Organon,  Dublin,  Ireland).  However,  her tidal vol-
ume was inadequate and she was unable to open her 
eyes spontaneously.  Accordingly,  Sugammadex (1 
mg/kg iv) was given,  and about 1-2min later,  tidal 
volume was suﬃcient and eye opening was possible.  
Following extubation,  she was monitored closely in the 
post-anesthetic care unit for 60min and then trans-
ferred to an intensive care unit.  Arterial blood gases 
and other biochemistry values were within normal 
limits following extubation.  The patient remained in 
the intensive care unit for a day and was discharged 
from the hospital on the 4th postoperative day.
Discussion
　 In our patient with ALS,  ﬁ ndings from neuromus-
cular monitoring of the extremities were incompatible 
with clinical ﬁndings.  During anesthetic induction,  
0.3mg/kg of rocuronium was suﬃcient to prevent a 
TOF response,  but was not suﬃcient for tracheal 
intubation.  During anesthetic emergence,  TOF 
re sponse was ＞0.9,  but spontaneous respiration was 
not enough to allow extubation.
　 ALS is the most common motor neuron disease and 
has a slowly progressive nature with a mean survival 
of approximately 3 year [2],  but disease progression 
is highly variable.  Age and site a onset are known to 
be the most important prognostic factors [1,  2].  In 
our patient,  onset was before the ﬁfth decade and with 
no evident signs of bulbar involvement,  such as slur-
ring of speech,  which leads to impaired airway pro-
tection and is known as a poor prognostic factor.  
Weakness of respiratory muscles can also lead to 
respiratory failure and death [4].  Although,  our 
patient had a young onset mainly in her limbs,  she had 
advanced muscle weakness and complained of 
dyspnea, and was evaluated as NYHA functional class 
III.  Considering the relatively low PaO2 result in the 
preoperative arterial blood gas analysis (64.1mmHg),  
we concluded that ALS was aggravated enough to 
involve the respiratory muscles.
　 We chose to use total intravenous anesthesia 
(TIVA) with propofol and remifentanil in this case.  A 
previous clinical study reported that ideal intubating 
conditions without muscle relaxants can be achieved 
with propofol 3mg/kg,  fentanyl 2µg/kg,  and lido-
caine 1.5mg kg without signiﬁcant hemodynamic 
changes [5].  Lee et al.  [6] reported a case of TIVA 
without muscle relaxant in ALS patients and deter-
mined eﬀect site concentrations of remifentanil and 
propofol of 5.5 and 5.0ng/ml for tracheal intubation.  
However,  in our patient blood pressures were sub-
normal even after the administration of ephedrine,  and 
we could not use high doses of propofol or  remifenta-
nil to avoid neuromuscular blocking agents.
　 Our patient had been taking phenytoin to stabilize 
nonspeciﬁc muscle cramps for several years.  Chronic 
phenytoin therapy increases the clearance of neuro-
muscular blocking agents and reduces patient sensitiv-
ity to the circulating concentration of neuromuscular 
blocking agent (NMBA),  which leads to rapid recovery 
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from paralysis [7-9].  However,  in ALS patients,  
vulnerability to NMBA and to medications used to 
control abnormal neuromuscular movements should be 
considered.
　 Previous cases reports on ALS patients have 
shown that monitoring of neuromuscular function dur-
ing general anesthesia is vital for proper titration of 
anesthetic agents,  including NMBA [3,  6,  10].  
However,  because the site of onset,  rate of disease 
progression,  and involvement sites vary considerably 
in ALS patients,  clinicians must interpret neuromus-
cular monitoring results very carefully.  Kelsaka et al.  
[3] reported a case in which the TOF ratio was 
incompatible with clinical ﬁndings in an ALS patient.  
More speciﬁcally,  when the TOF ratio exceeded 0.90,  
the depth of respiration was insuﬃcient and the 
patient was unable to open his eyes [3].  In our case,  
we also experienced discordance between the TOF 
response and clinical ﬁndings during anesthetic induc-
tion and emergence.
　 Cholinesterase inhibitors are commonly used to 
reverse residual NMBA eﬀects.  This agent inacti-
vates acetylcholinesterase (AChE),  which is respon-
sible for the breakdown of Ach,  and for displacing 
NMBA molecules to Ach from the nicotinic receptors.  
Because the NMBA has longer duration of action than 
cholinesterase inhibitors,  there is a risk of recura-
rization.  Sugammadex is a new selective relaxant 
binding agent that directly encapsulates and inacti-
vates NMBA,  and thus,  prevents recurarization 
without cholinergic side eﬀects [11].  In our patient,  
we could not diﬀerentiate remnant NMBA from dis-
ease progression,  but excluding the risk of recura-
rization or remnant NMBA function by administering 
a smaller than recommended dose (2-4mg/kg) of sug-
ammadex proved helpful.
　 In conclusion,  careful consideration of disease 
progression and drug interactions are important for 
the anesthetic management of ALS.  Clinical symptoms 
and signs must be given preference over data from 
monitoring devices.
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